SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-083250
Filing Date
2023-07-24
Accepted
2023-07-24 09:00:26
Documents
12
Period of Report
2023-07-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2321842d1_8k.htm   iXBRL 8-K 25141
  Complete submission text file 0001104659-23-083250.txt   199804

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20230721.xsd EX-101.SCH 3012
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20230721_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20230721_pre.xml EX-101.PRE 22357
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2321842d1_8k_htm.xml XML 3473
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 231103866
SIC: 2834 Pharmaceutical Preparations